| Literature DB >> 34906085 |
Ahmad Farajzadeh Sheikh1,2, Robab Rahimi3,4, Hossein Meghdadi5,6,7, Ameneh Alami1,2, Morteza Saki8,9,10.
Abstract
BACKGROUND: This study aimed to evaluate the occurrence of Streptococcus pneumoniae and Haemophilus influenzae in sputum of patients with community-acquired pneumonia (CAP) using culture and multiplex polymerase chain reaction (M-PCR) methods and to survey the antibiotic resistance patterns of aforesaid isolates. RESULT: In total, 23.9 % (n = 22/92) of sputum samples showed positive results in the culture method. S. pneumoniae and H. influenzae were isolated from 15 (16.3 %) and 7 (7.6%) samples, respectively. Using M-PCR, 44 (47.8 %) samples were positive for S. pneumoniae and H. influenzae. Of these, S. pneumoniae and H. influenzae were detected in 33 (35.8%) and 11 (11.9%) of the sputum samples, respectively. The sensitivity, specificity, and accuracy rates of PCR in detection of S. pneumoniae in comparison with culture method were 100, 76.6, and 83.6%, respectively. While, the sensitivity, specificity, and accuracy rates of PCR in detection of H. influenzae in comparison with culture method were 100, 95.3, and 95.8%, respectively. Out of 11 isolates of H. influenzae, two strains confirmed as H. influenzae type b (Hib) and 3 isolates were type f. However, 6 isolates were non-typable. The co-trimoxazole and amoxicillin/clavulanate were the less effective antibiotics against S. pneumonia and H. influenzae, respectively. Ceftriaxone with 13.3% resistance rates was the most effective antibiotic against S. pneumoniae, while, clarithromycin, ceftriaxone, and gentamicin with resistance rates of 28.6% for each one were the most effective chemicals against H. influenzae isolates.Entities:
Keywords: CAP; Community-acquired pneumonia; Haemophilus influenzae; Multiplex polymerase chain reaction; Streptococcus pneumoniae
Mesh:
Substances:
Year: 2021 PMID: 34906085 PMCID: PMC8670030 DOI: 10.1186/s12866-021-02408-7
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
The primer sets used in this study
| Target | Primer sequence | Amplicon size | Reference |
|---|---|---|---|
5´-GGCTACTGGTACGTACATTC-3´ 5´-AATCAAGCCATCTGGCTCTA-3´ | 395bp | [ | |
| P6 | 5´- ACTTTTGGCGGTTACTCTGT-3´ 5´- TGTGCCTAATTTACCAGCAT-3´ | 273bp | [ |
HI-1-5'-CGTTTGTATGATGTTGATCCAGAC-3' HI-2-5'-TGTCCATGTCTTCAAAATGATG-3' | 343bp | [ | |
| Type a | a1-5'-CTACTCATTGCAGCATTTGC-3' a2-5'-GAATATGACCTGATCTTCTG-3' | 250bp | [ |
| Type b | b1-5'-GCGAAAGTGAACTCTTATCTCTC-3' b2-5'-GCTTACGCTTCTATCTCGGTGAA-3' | 480bp | [ |
| Type c | c1-5'-TCTGTGTAGATGATGGTTCA-3' c2-5'-CAGAGGCAAGCTATTAGTGA-3' | 250bp | [ |
| Type d | d1-5'-TGATGACCGATACAACCTGT-3' d2-5'-TCCACTCTTCAAACCATTCT-3' | 150bp | [ |
| Type e | e1-5'-GGTAACGAATGTAGTGGTAG-3' e2-5'-GCTTTACTGTATAAGTCTAG-3' | 1350bp | [ |
| Type f | f1-5'-GCTACTATCAAGTCCAAATC-3' f2-5'-CGCAATTATGGAAGAAAGCT-3' | 450bp | [ |
Test performance of multiplex polymerase chain reaction (M-PCR) in detection of Streptococcus pneumoniae and Haemophilus influenzae compared to culture method
| Culture for | Culture for | |||||
|---|---|---|---|---|---|---|
| Positive | Negative | Total | Positive | Negative | Total | |
| 15 (16.3%) | 18 (19.5%) | 33 (35.8%) | 7 (7.6%) | 4 (4.3%) | 11 (11.9%) | |
| 0 (0.0%) | 59 (64.2%) | 59 (64.2%) | 0 (0.0%) | 81 (88.1%) | 81 (88.1%) | |
| 15 (16.3%) | 77 (83.7%) | 92 (100%) | 7 (7.6%) | 85 (92.4%) | 92 (100%) | |
| 100.0% (89.4 to 100.0%) | 100.0% (71.5 to 100.0%) | |||||
| 76.6% (65.6 to 85.5%) | 95.3% (88.4 to 98.7%) | |||||
| 64.7% (55.0 to 73.3%) | 73.3% (51.4 to 87.7%) | |||||
| 100.0% | 100.0% | |||||
| 4.3% (2.9 to 6.4%) | 21.3% (8.2 to 55.3%) | |||||
| 0.0% | 0.0% | |||||
| 83.6% (75.4 to 90.0%) | 95.8% (89.7 to 98.9%) | |||||
Sensitivity patterns of Streptococcus pneumoniae and Haemophilus influenza isolates
| Antimicrobial agents | Susceptible/Resistant | ||
|---|---|---|---|
| Ciprofloxacin | S | Not recommended by CLSI | 3 (42.9%) |
| R | 4 (57.1%) | ||
| Amoxicillin/clavulanate | S | 10 (66.7%) | 1 (14.3%) |
| R | 5 (33.3%) | 6 (85.7%) | |
| Clarithromycin | S | 6 (40%) | 5 (71.4%) |
| R | 9 (60%) | 2 (28.6%) | |
| Ceftriaxone | S | 13 (86.7%) | 5 (71.4%) |
| R | 2 (13.3%) | 2 (28.6%) | |
| Co- trimoxazole | S | 4 (26.7%) | 4 (57.1%) |
| R | 11 (73.3%) | 3 (42.9%) | |
| Erythromycin | S | 7 (46.7%) | Not recommended by CLSI |
| R | 8 (53.3%) |
CLSI Clinical and laboratory standards institute